顺铂联合红霉素治疗恶性胸腔积液疗效观察

Therapeutic effects of thoracic cavity injection of cisplatin and erythromycinum in malignant pleural effusion

目的观察顺铂联合红霉素胸腔灌注治疗恶性胸腔积液的临床疗效和毒副反应。方法采用胸腔闭式引流术,胸液小于50 m l/24小时引流,治疗组(22例)在胸腔注入顺铂60 mg、红霉素1.0,对照组(20例)在胸腔注入顺铂60 mg,每周1次,共1-3次。观察疗效、生活质量、生存率及毒副反应。结果治疗组有效率为85%显著高于对照组的50%(P<0.05),治疗组6个月复发率明显低于对照组,差异有显著性(P<0.05),两组治疗后Karnofsky评分明显提高,但两组差异无显著性(P>0.05),两组无严重不良反应,均可耐受。结论顺铂和红霉素联合胸膜腔内注射,消除胸水作用明显,值得临床推广。

Objection To evaluate the therapeutic effect and side effect of thoracic cavity injection of cisplatin and erythromycinum in malignant pleural effusion. Methods In therapy group, 22 cases with malignant pleural effusion, after chest drainage, were injected into pleural cavity with erythromycinum 1.0 and cisplatin 60 mg weekly for 1 - 3 weeks, and in control group （20 cases） were injected only with cisplatin 60 mg for 1-3 weeks. The efficacy,quality of life,relapse rate and toxicities were evaluated. Results The response rate in therapy group was higher than that in control group significantly （81.82% to 50%, P 〈0. 05）, and the relapse rate after 6 months in treatment group was lower than that in the control group （ P 〈 0. 05 ）. The Karnofsky scores of two groups after treatment improved apparently, but there was not statistical significance between two groups （ P 〉 0. 05 ）. The toxicities of two groups were tolerated. Conclusion The thoracic cavity injection of cisplafin and erythromycinum in malignant pleural effusion is an effective way and worth in clinical application.